| | PharmaBoardroom Interview with BHI’s Rich Bendis | Rich Bendis, CEO and founder of BioHealth Innovation, discusses how the BioHealth Capital Region has grown into a leading US life sciences hub by connecting Maryland, Washington, D.C., and Northern Virginia through a regional, collaborative approach. From supporting early-stage companies with non-dilutive funding and... | | |
There’s still time to showcase your organization at the region’s premier industry event. Sponsorship opportunities for BioHealth Capital Region Week 2025 (September 23–25 at US Pharmacopeia in Rockville, MD) are filling quickly, but select tiers and table options remain available.
Becoming a sponsor positions your brand in front of hundreds of leaders from across the life sciences ecosystem, including C-level executives, government agencies, academic institutions, entrepreneurs, and investors. Sponsors receive visibility across all three signature events, the Forum, Crab Trap, and Investment Conference, along with access to VIP networking and leadership opportunities.
Interested in learning more? Contact Rich Bendis at rbendis@biohealthinnovation.org and Andy Eckert at aeckert@biohealthinnovation.org.
| | Register now for the BioHealth Capital Region Investment Conference | Don’t miss the 2025 BioHealth Capital Region Investment Conference on September 25th in Rockville, MD. This exclusive event connects startups with leading investors through curated one-on-one meetings, networking, and quick-pitch presentations. It’s the best opportunity of the year to showcase your company, explore partnerships, and gain direct access to capital. | |  | Final Week to Apply for the Crab Trap Competition - Applications due by 8/29 | This is the final week to apply for the 2025 Crab Trap Competition, with submissions closing on August 29th. Startups in diagnostics, therapeutics, devices, and health solutions will compete for prizes including $10,000 in cash, $25,000 in IT services from InfoPathways, and $10,000 in CRO services from Noble Life Sciences and Accelevir. Don’t miss this chance for visibility and investor exposure—apply now | | |
Join Us for the BHCR Forum: Where Human and Artificial Intelligence Converge | Be part of the 11th Annual BioHealth Capital Region Forum, September 23–24, 2025, at US Pharmacopeia in Rockville, MD. This year’s theme, Where Human and Artificial Intelligence Converge in the BioHealth Industry, will explore groundbreaking advances shaping the future of healthcare. Connect with industry leaders, investors, government, and academia, and gain insights you can apply to your own organization. Attendance is free thanks to our sponsors, but space is limited — secure your spot today | | | TEDCO Invests in AGED Diagnostics | COLUMBIA, Md., (August 19, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Pre-Seed Builder Fund investment in AGED Diagnostics. Housed under TEDCO’s Social Impact Funds, the Pre-Seed Builder Funds provide investment and support to Maryland-based technology companies led by founders from economically underserved backgrounds. | | | NIH Technology Opportunity Webinar: A Drug Repurposing Approach for Clinical Treatment of Triple-Negative Breast Cancer | Wednesday, September 10, 2025 11:00 AM - 12:00 PM - Register for a free NIH technology webinar to learn about a potential, novel treatment for Triple Negative Breast Cancer (TNBC). William Reinhold and his team at the National Cancer Institute repurposed | | | The BioHealth Capital Region Maintains Top 3 Spot in GEN’s 2025 U.S. Biopharma Cluster Rankings | For the third consecutive year, the BioHealth Capital Region (BHCR), encompassing Maryland, Virginia, and Washington, D.C., has earned a Top 3 position in the highly regarded “Top 10 U.S. Biopharma Clusters” list by Genetic Engineering & Biotechnology News (GEN). | | | Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) | Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder (AUD). Fast Track designation is intended to accelerate the development and review of new drugs that target serious conditions and address unmet medical needs. | | |
Pfizer - Ever Wonder How Drugs Get Their Names?
|
What’s in a name?
When it comes to naming drug products, the answer is rarely simple. Just as all potential drugs go through rigorous safety assessments during their development, so do their names. That’s why a single name for a drug candidate can take years to get approval from regulatory authorities, in an entirely separate process from the approval of the drug, itself.
| | |
360Dx - BARDA Diagnostics Accelerator Seeks Second Cohort After Awarding Top Prizes
| |
NEW YORK – An accelerator program supported by the US
Department of Health and Human Services' Biomedical Advanced
Research and Development Authority (BARDA) fostering new
health security diagnostics has recently graduated its inaugural
cohort and is now seeking proposals from early-stage startups and university-backed projects.
| | |
Introduction to Technology Transfer and Commercialization Fall 2025 Course
| |
The Technology Transfer Society – Washington D.C. Chapter will be offering an Introduction to Technology Transfer and Commercialization Fall 2025 Course in conjunction with Montgomery College. The course will be given in a hybrid format to allow for both virtual and in-person attendance.
This course is intended to provide students with an overview....
| | | | | |
